Mika Derynck
Direktor/Vorstandsmitglied bei ENLIVEN THERAPEUTICS, INC.
Vermögen: - $ am 30.04.2024
Profil
Mika Kakefuda Derynck is currently working as a Director and Independent Director at Enliven Therapeutics, Inc. and as the Chief Medical Officer at Amunix Pharmaceuticals, Inc. She completed her undergraduate degree at Boston University and her doctorate at Boston University School of Medicine.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
08.04.2024 | 0 ( -.--% ) | - $ | 30.04.2024 |
Aktive Positionen von Mika Derynck
Unternehmen | Position | Beginn |
---|---|---|
ENLIVEN THERAPEUTICS, INC. | Direktor/Vorstandsmitglied | 23.02.2023 |
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Direktor/Vorstandsmitglied | 19.01.2022 |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Technik-/Wissenschafts-/F&E-Leiter | - |
Ausbildung von Mika Derynck
Boston University | Undergraduate Degree |
Boston University School of Medicine | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ENLIVEN THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 2 |
---|---|
Enliven Therapeutics, Inc. /US/
Enliven Therapeutics, Inc. /US/ BiotechnologyHealth Technology EnLiven Therapeutics, Inc. engages in the discovery and development of small molecule treatments for cancer. The company was founded by Samuel S. Kintz and is headquartered in San Francisco, CA. | Health Technology |
Amunix Pharmaceuticals, Inc.
Amunix Pharmaceuticals, Inc. BiotechnologyHealth Technology Amunix Pharmaceuticals, Inc. manufactures and fabricates drugs. The firm’s pipeline products are based on proprietary XTEN half-life extension, Antibody-XTEN-Drug Conjugate, ProTIA pro-drug and bispecific T-cell engager platform technologies. The company was founded by Willem P.C. Stemmer and Volker Schellenberger in 2006 and is headquartered in Mountain View, CA. | Health Technology |